Broadcast Date: 
  • Time: 

Decades since the discovery of messenger RNA, mRNA-based therapeutics catapulted to the forefront of public consciousness in the form of vaccines to combat the COVID-19 pandemic. The potential for the therapeutic use of mRNA seems to be endless and an ever-growing number of indications are now entering the clinical pipelines. To be ready for such rapid growth, the need for scalable purification solutions for commercial production continues to rise.

To support the development of mRNA therapeutics, a novel affinity resin to isolate and purify mRNA has been developed. Designed for scalable purification processes, POROS™ Oligo dT(25) affinity resin binds mRNA through a simple AT base-pairing mechanism.

During this GEN webinar, we will take a closer look at the advantages of affinity capture of mRNA and demonstrate how this affinity resin can help to maximize efficiency and simplify your mRNA purification process from bench to manufacturing.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Thermo Fisher Scientific logo

Sirat Sikka
Sirat Sikka
Field Application Scientist
Thermo Fisher Scientific